Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021

• Type of Material: Article
• Authors: Paolo A Ascierto, Ist Nazl Tumori IRCCS Fdn G Pascale; Antonio Avallone, Ist Nazl Tumori IRCCS Fdn G Pascale; Nina Bhardwaj, Icahn School of Medicine at Mount Sinai; Carlo Bifulco, Providence Genom & Earle A Chiles Res Inst; Sergio Bracarda, Azienda Ospedaliera Santa Maria; Joshua D Brody, Icahn School of Medicine at Mount Sinai; Luigi Buonaguro, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale; Sandra Demaria, Weill Cornell Medical College; Leisha A Emens, Magee Women’s Hospital; Robert L Ferris, UPMC Hillman Cancer Center; Jérôme Galon, Sorbonne Universite; Samir N Khleif, Georgetown University; Christopher A Klebanoff, Weill Cornell Medical College; Tamara Laskowski, Lonza Global; Ignacio Melero, Clinica Universidad de Navarra and CIBERONC; Chrystal Paulos, Emory University; Sandro Pignata, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale; Marco Ruella, University of Pennsylvania; Inge Marie Svane, Copenhagen University Hospital; Janis M Taube, ohns Hopkins University SOM; Bernard A Fox, Providence Cancer Institute; Patrick Hwu, Moffitt Cancer Center; Igor Puzanov, Roswell Park Comprehensive Cancer Center
• Language: English
• Date: 2022-06-07
• Publisher: BMC
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2022
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1186/s12967-022-03471-y
• Title of Journal or Parent Work: JOURNAL OF TRANSLATIONAL MEDICINE
• Volume: 20
• Issue: 1
• Start Page: 257
• End Page: 257
• Grant/Funding Information: Not applicable.
• Keywords: OVARIAN-CANCER; Science & Technology; Vaccine; Immunotherapy; SQUAMOUS-CELL CARCINOMA; Life Sciences & Biomedicine; Research & Experimental Medicine; Biomarkers; STAGE-III; INFILTRATING T-CELLS; PLUS CHEMOTHERAPY; NIVOLUMAB; Combination therapy; ESOPHAGEAL; Medicine, Research & Experimental; Tumor microenvironment; OPEN-LABEL; Checkpoint inhibitors; HEAD; GASTROESOPHAGEAL JUNCTION
• Research Categories: Health Sciences, Oncology; Health Sciences, Medicine and Surgery

Abstract

Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients with different cancers has focused attention on the potential for other immunotherapeutic approaches. These include inhibitors of additional immune checkpoints, adoptive cell transfer (ACT), and therapeutic vaccines. Patients with advanced cancers who previously had limited treatment options available may now benefit from immunotherapies that can offer durable responses and improved survival outcomes. However, despite this, a significant proportion of patients fail to respond to immunotherapy, especially those with less immunoresponsive cancer types, and there remains a need for new treatment strategies. The virtual Immunotherapy Bridge (December 1st–2nd, 2021), organized by the Fondazione Melanoma Onlus, Naples, Italy in collaboration with the Society for Immunotherapy of Cancer addressed several areas of current research in immunotherapy, including lessons learned from cell therapies, drivers of immune response, and trends in immunotherapy across different cancers, and these are summarised here.